falsefalse

Advancements in the Treatment of Desmoid Tumors - Episode 10

Targeting NOTCH Pathway Signaling with Nirogacestat

, , ,

Mark Agulnik, MD, examines the mechanism of action of nirogacestat, emphasizing the impact of ϒ-secretase inhibition on NOTCH pathway signaling.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of the Landscape Surrounding Desmoid Tumors
    EP. 2: Expert Perspectives on the Pathogenesis and Diagnosis of Desmoid Tumors
    EP. 3: Signs and Symptoms of Desmoid Tumors and Their Impact on Quality of Life
    EP. 4: Active Surveillance in Frontline Management of Desmoid Tumors
    EP. 5: The Evolving Role of Surgery in the Management of Desmoid Tumors
    EP. 6: Treatment Strategies Using Radiotherapy or Other Locoregional Approaches in Desmoid Tumors
    EP. 7: Approaches to Systemic Therapy in Desmoid Tumors: The Role of Chemotherapy
    EP. 8: The Role of Supportive Care Measures in Patients with Desmoid Tumors
    EP. 9: Desmoid Tumors in Women: Special Considerations for Pregnancy and Contraception
    Now Viewing
    EP. 10: Targeting NOTCH Pathway Signaling with Nirogacestat
    EP. 11: DeFi: Nirogacestat in Patients with Progressing Desmoid Tumors
    EP. 12: Impact of Nirogacestat on Pain, Quality of Life, and Fertility in Patients with Desmoid Tumors
    EP. 13: Nirogacestat's Impact on the Future Treatment of Desmoid Tumors
    EP. 14: Future Perspectives on the Treatment of Desmoid Tumors

    Related Content:

    Advancements in the Treatment of Desmoid TumorsOncLive Peer Exchange®
    Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial
    Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL
    Timing and Candidacy for AlloHSCT in MDS
    x